Neurofibromatosis Type 2 Clinical Trial
Official title:
The Effect of Changes in Head Position on Magnetic Resonance Image Distortion in Patients With Auditory Implants
Verified date | March 2020 |
Source | Manchester University NHS Foundation Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients with Neurofibromatosis type 2 (NF2) almost always develop acoustic neuromas in both
ears. As a result of the tumours themselves or the treatment of the tumours, many patients
become profoundly deaf in both ears. It is possible to restore a degree of hearing by placing
a hearing implant in the brainstem adjacent to the hearing pathways within the brain. This is
termed an auditory brainstem implant (ABI).
The aim of this study is to find the optimum head position in relation to the MRI magnet
field, which would produce least area of image distortion in patients with ABIs. This will be
of benefit in optimising the MR imaging in future patients with implants.
Status | Completed |
Enrollment | 5 |
Est. completion date | January 31, 2015 |
Est. primary completion date | January 31, 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Any patient over the age of 18 with NF2 who has an auditory implant (cochlear or auditory brainstem implant) in situ and requires MRI scanning. Exclusion Criteria: Children under the age of 18 years Claustrophobia Bilateral implants Contraindications and relative contraindications for MRI (as per the Radiology Department MRI protocol) including: Pacemaker Certain metallic heart valves Ferromagnetic implanted materials and foreign bodies |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Central Manchester University Hospitals NHS Foundation Trust | Manchester | Manchester (Manchester Borough) |
Lead Sponsor | Collaborator |
---|---|
Manchester University NHS Foundation Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To study the effect of magnet orientation in auditory brainstem implants/ cochlear implants in determining the size of signal void seen on MRI scanning. | 1 year | ||
Secondary | To identify if there is an angle at which the signal void is minimised | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05521048 -
Doxycycline in Cutaneous Schwannoma (NF2)
|
Phase 1/Phase 2 | |
Completed |
NCT01207687 -
Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)
|
Phase 2 | |
Completed |
NCT01767792 -
Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
|
Phase 2 | |
Active, not recruiting |
NCT01552434 -
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
|
Phase 1 | |
Completed |
NCT01880749 -
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
|
Early Phase 1 | |
Recruiting |
NCT05130866 -
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
|
Phase 2/Phase 3 | |
Recruiting |
NCT04374305 -
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
|
Phase 2 | |
Completed |
NCT01125046 -
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
|
Phase 2 | |
Completed |
NCT03210285 -
WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data
|
||
Completed |
NCT02934256 -
Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
|
Phase 2 | |
Terminated |
NCT01345136 -
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
|
Phase 2 | |
Completed |
NCT02104323 -
Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
|
Phase 2 | |
Terminated |
NCT02282917 -
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
|
Early Phase 1 | |
Completed |
NCT02129647 -
Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
|
Phase 2 | |
No longer available |
NCT02589912 -
Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients
|